<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01513551</url>
  </required_header>
  <id_info>
    <org_study_id>V114-002</org_study_id>
    <secondary_id>2011-004542-18</secondary_id>
    <secondary_id>V114-002</secondary_id>
    <nct_id>NCT01513551</nct_id>
  </id_info>
  <brief_title>The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)</brief_title>
  <official_title>A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX® 23) and PREVNAR 13® (Pneumococcal 13-Valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in Healthy Adults 50 Years of Age or Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to see if an investigational vaccine for Streptococcus pneumonia
      disease (V114) has comparable safety, tolerability, and antibody response to Pneumococcal
      Polysaccharide Vaccine (PNEUMOVAX® 23) and 13-valent Pneumococcal Conjugate Vaccine (PREVNAR
      13®) when administered to healthy adults 50 years of age or older.

      The primary hypothesis is the serotype-specific immunoglobulin G (IgG) geometric mean
      concentrations (GMCs) as measured by the pneumococcal electrochemiluminescence (Pn ECL) assay
      at one month postvaccination in subjects who receive V114 will be noninferior to those
      measured in subjects who receive PNEUMOVAX® 23.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 13, 2012</start_date>
  <completion_date type="Actual">February 15, 2013</completion_date>
  <primary_completion_date type="Actual">February 15, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With an Adverse Event</measure>
    <time_frame>All AEs: up to 14 days after vaccination; Serious Adverse Events (SAEs): up to 6 months after vaccination</time_frame>
    <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse experience.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With an Injection-site Adverse Event Reported With &gt;=2% Incidence in One or More Vaccination Groups</measure>
    <time_frame>Up to Day 14 postvaccination</time_frame>
    <description>Injection-site AEs reported by &gt;=2% of participants in one or more vaccination groups were assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Systemic Adverse Event Reported With &gt;=2% Incidence in One or More Vaccination Groups</measure>
    <time_frame>Up to Day 14 postvaccination</time_frame>
    <description>Systemic AEs reported by &gt;=2% of participants in one or more vaccination groups were assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Serious Adverse Event</measure>
    <time_frame>Up to 6 months postvaccination</time_frame>
    <description>A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With a Vaccine-related Serious Adverse Event</measure>
    <time_frame>Up to 6 months postvaccination</time_frame>
    <description>A SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. SAEs deemed by the investigator to be possibly, probably, or definitely related to study vaccine were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG) Antibodies</measure>
    <time_frame>One month postvaccination</time_frame>
    <description>Pneumococcal serotype-specific IgG was measured in serum using an electrochemiluminescence (ECL) assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) of Pneumococcal Serotype-specific Opsonophagocytic Activity (OPA) Antibodies</measure>
    <time_frame>One month postvaccination</time_frame>
    <description>OPA for the serotypes contained in V114 was determined using a Multiplex Opsonophagocytic Assay (MOPA-4)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">692</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>V114</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PNEUMOVAX® 23</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PNEUMOVAX® 23 on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PREVNAR 13®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PREVNAR 13® on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal Conjugate Vaccine (V114)</intervention_name>
    <description>15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.</description>
    <arm_group_label>V114</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PNEUMOVAX® 23</intervention_name>
    <description>23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose.</description>
    <arm_group_label>PNEUMOVAX® 23</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PREVNAR 13®</intervention_name>
    <description>13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.</description>
    <arm_group_label>PREVNAR 13®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Without fever for 72 hours prior to vaccination

        Exclusion Criteria:

          -  Prior receipt of any pneumococcal polysaccharide vaccine or any pneumococcal conjugate
             vaccine

          -  Known or suspected to be immunocompromised

          -  Functional or anatomic asplenia

          -  History of autoimmune disease

          -  Evidence of dementia or cognitive impairment

          -  Use of any immunosuppressive therapy

          -  Received a licensed non-live vaccine administered within the 14 days prior to receipt
             of study vaccine or scheduled to receive any other licensed vaccine within 30 days
             following receipt of study vaccine

          -  Received a licensed live virus vaccine within 30 days prior of receipt of study
             vaccine or is scheduled to receive any other licensed vaccine within 30 days of
             receipt of study vaccine

          -  Received any vaccine containing diphtheria toxoid within 6 months prior to receipt of
             study vaccine

          -  Received a blood transfusion or blood products within the 6 months before receipt of
             study vaccine or scheduled to receive a blood transfusion or blood product within 30
             days of receipt of study vaccine

          -  History of invasive pneumococcal disease or known history of other culture-positive
             pneumococcal disease

          -  Received antibiotic therapy for any acute illness within 72 hours before receipt of
             study vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>December 27, 2011</study_first_submitted>
  <study_first_submitted_qc>January 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2012</study_first_posted>
  <results_first_submitted>November 26, 2018</results_first_submitted>
  <results_first_submitted_qc>November 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 13, 2018</results_first_posted>
  <last_update_submitted>November 26, 2018</last_update_submitted>
  <last_update_submitted_qc>November 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumococcal vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This trial was conducted at 25 trial centers: 10 in the United States; 2 in Canada; 2 in Denmark; 2 in Israel; 2 in Norway, 3 in Poland, 2 in Spain and 2 in Sweden.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>V114</title>
          <description>Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>PNEUMOVAX® 23</title>
          <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PNEUMOVAX® 23 on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>PREVNAR 13®</title>
          <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PREVNAR 13® on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
                <participants group_id="P2" count="231"/>
                <participants group_id="P3" count="231"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
                <participants group_id="P2" count="231"/>
                <participants group_id="P3" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="225"/>
                <participants group_id="P3" count="226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis population consisted of all randomized participants who received study vaccine.</population>
      <group_list>
        <group group_id="B1">
          <title>V114</title>
          <description>Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>PNEUMOVAX® 23</title>
          <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PNEUMOVAX® 23 on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>PREVNAR 13®</title>
          <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PREVNAR 13® on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="230"/>
            <count group_id="B2" value="231"/>
            <count group_id="B3" value="230"/>
            <count group_id="B4" value="691"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>50 to 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 to 74 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="367"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="216"/>
                    <measurement group_id="B2" value="211"/>
                    <measurement group_id="B3" value="215"/>
                    <measurement group_id="B4" value="642"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="217"/>
                    <measurement group_id="B3" value="212"/>
                    <measurement group_id="B4" value="641"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an Adverse Event</title>
        <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse experience.</description>
        <time_frame>All AEs: up to 14 days after vaccination; Serious Adverse Events (SAEs): up to 6 months after vaccination</time_frame>
        <population>The analysis population consisted of those participants who received study vaccination and had safety follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PNEUMOVAX® 23</title>
            <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PNEUMOVAX® 23 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PREVNAR 13®</title>
            <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PREVNAR 13® on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Adverse Event</title>
          <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the Sponsor's product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the Sponsor's product, is also an adverse experience.</description>
          <population>The analysis population consisted of those participants who received study vaccination and had safety follow-up.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1"/>
                    <measurement group_id="O2" value="68.3"/>
                    <measurement group_id="O3" value="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>6.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>15.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>9.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>17.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an Injection-site Adverse Event Reported With &gt;=2% Incidence in One or More Vaccination Groups</title>
        <description>Injection-site AEs reported by &gt;=2% of participants in one or more vaccination groups were assessed.</description>
        <time_frame>Up to Day 14 postvaccination</time_frame>
        <population>The analysis population consisted of those participants who received study vaccination and had safety follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PNEUMOVAX® 23</title>
            <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PNEUMOVAX® 23 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PREVNAR 13®</title>
            <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PREVNAR 13® on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Injection-site Adverse Event Reported With &gt;=2% Incidence in One or More Vaccination Groups</title>
          <description>Injection-site AEs reported by &gt;=2% of participants in one or more vaccination groups were assessed.</description>
          <population>The analysis population consisted of those participants who received study vaccination and had safety follow-up.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="14.8"/>
                    <measurement group_id="O3" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="10.4"/>
                    <measurement group_id="O3" value="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.3"/>
                    <measurement group_id="O2" value="51.3"/>
                    <measurement group_id="O3" value="53.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1"/>
                    <measurement group_id="O2" value="10.9"/>
                    <measurement group_id="O3" value="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site warmth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Systemic Adverse Event Reported With &gt;=2% Incidence in One or More Vaccination Groups</title>
        <description>Systemic AEs reported by &gt;=2% of participants in one or more vaccination groups were assessed.</description>
        <time_frame>Up to Day 14 postvaccination</time_frame>
        <population>The analysis population consisted of those participants who received study vaccination and had safety follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PNEUMOVAX® 23</title>
            <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PNEUMOVAX® 23 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PREVNAR 13®</title>
            <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PREVNAR 13® on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Systemic Adverse Event Reported With &gt;=2% Incidence in One or More Vaccination Groups</title>
          <description>Systemic AEs reported by &gt;=2% of participants in one or more vaccination groups were assessed.</description>
          <population>The analysis population consisted of those participants who received study vaccination and had safety follow-up.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.5"/>
                    <measurement group_id="O2" value="43.9"/>
                    <measurement group_id="O3" value="45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Serious Adverse Event</title>
        <description>A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.</description>
        <time_frame>Up to 6 months postvaccination</time_frame>
        <population>The analysis population consisted of those participants who received study vaccination and had safety follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PNEUMOVAX® 23</title>
            <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PNEUMOVAX® 23 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PREVNAR 13®</title>
            <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PREVNAR 13® on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Serious Adverse Event</title>
          <description>A serious adverse event (SAE) is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.</description>
          <population>The analysis population consisted of those participants who received study vaccination and had safety follow-up.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="3.0"/>
                    <measurement group_id="O3" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a Vaccine-related Serious Adverse Event</title>
        <description>A SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. SAEs deemed by the investigator to be possibly, probably, or definitely related to study vaccine were reported.</description>
        <time_frame>Up to 6 months postvaccination</time_frame>
        <population>The analysis population consisted of those participants who received study vaccination and had safety follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PNEUMOVAX® 23</title>
            <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PNEUMOVAX® 23 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PREVNAR 13®</title>
            <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PREVNAR 13® on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Vaccine-related Serious Adverse Event</title>
          <description>A SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. SAEs deemed by the investigator to be possibly, probably, or definitely related to study vaccine were reported.</description>
          <population>The analysis population consisted of those participants who received study vaccination and had safety follow-up.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG) Antibodies</title>
        <description>Pneumococcal serotype-specific IgG was measured in serum using an electrochemiluminescence (ECL) assay.</description>
        <time_frame>One month postvaccination</time_frame>
        <population>The analysis population consisted of those participants who were not considered to have violated important protocol requirements that could have impacted the validity of the antibody response measured following vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PNEUMOVAX® 23</title>
            <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PNEUMOVAX® 23 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PREVNAR 13®</title>
            <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PREVNAR 13® on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG) Antibodies</title>
          <description>Pneumococcal serotype-specific IgG was measured in serum using an electrochemiluminescence (ECL) assay.</description>
          <population>The analysis population consisted of those participants who were not considered to have violated important protocol requirements that could have impacted the validity of the antibody response measured following vaccination.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="207"/>
                    <count group_id="O3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.76" lower_limit="3.05" upper_limit="4.65"/>
                    <measurement group_id="O2" value="3.30" lower_limit="2.68" upper_limit="4.07"/>
                    <measurement group_id="O3" value="3.12" lower_limit="2.54" upper_limit="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="207"/>
                    <count group_id="O3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" lower_limit="0.96" upper_limit="1.35"/>
                    <measurement group_id="O2" value="0.57" lower_limit="0.47" upper_limit="0.68"/>
                    <measurement group_id="O3" value="0.56" lower_limit="0.47" upper_limit="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="207"/>
                    <count group_id="O3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" lower_limit="1.59" upper_limit="2.41"/>
                    <measurement group_id="O2" value="1.03" lower_limit="0.83" upper_limit="1.27"/>
                    <measurement group_id="O3" value="2.09" lower_limit="1.70" upper_limit="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="207"/>
                    <count group_id="O3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.99" lower_limit="3.23" upper_limit="4.92"/>
                    <measurement group_id="O2" value="2.70" lower_limit="2.21" upper_limit="3.30"/>
                    <measurement group_id="O3" value="2.76" lower_limit="2.21" upper_limit="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="207"/>
                    <count group_id="O3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.88" lower_limit="3.73" upper_limit="6.39"/>
                    <measurement group_id="O2" value="1.14" lower_limit="0.90" upper_limit="1.43"/>
                    <measurement group_id="O3" value="4.86" lower_limit="3.86" upper_limit="6.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="207"/>
                    <count group_id="O3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.43" lower_limit="4.11" upper_limit="7.17"/>
                    <measurement group_id="O2" value="2.01" lower_limit="1.58" upper_limit="2.57"/>
                    <measurement group_id="O3" value="2.81" lower_limit="2.19" upper_limit="3.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="207"/>
                    <count group_id="O3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.59" lower_limit="3.72" upper_limit="5.66"/>
                    <measurement group_id="O2" value="3.74" lower_limit="3.00" upper_limit="4.65"/>
                    <measurement group_id="O3" value="6.06" lower_limit="4.91" upper_limit="7.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="207"/>
                    <count group_id="O3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.05" lower_limit="3.32" upper_limit="4.93"/>
                    <measurement group_id="O2" value="2.72" lower_limit="2.21" upper_limit="3.36"/>
                    <measurement group_id="O3" value="3.41" lower_limit="2.77" upper_limit="4.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="207"/>
                    <count group_id="O3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.56" lower_limit="6.86" upper_limit="10.69"/>
                    <measurement group_id="O2" value="8.13" lower_limit="6.38" upper_limit="10.36"/>
                    <measurement group_id="O3" value="8.90" lower_limit="7.08" upper_limit="11.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="207"/>
                    <count group_id="O3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" lower_limit="6.62" upper_limit="9.68"/>
                    <measurement group_id="O2" value="4.66" lower_limit="3.73" upper_limit="5.82"/>
                    <measurement group_id="O3" value="6.83" lower_limit="5.68" upper_limit="8.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="207"/>
                    <count group_id="O3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.36" lower_limit="7.66" upper_limit="11.44"/>
                    <measurement group_id="O2" value="6.99" lower_limit="5.67" upper_limit="8.61"/>
                    <measurement group_id="O3" value="11.36" lower_limit="9.28" upper_limit="13.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="207"/>
                    <count group_id="O3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" lower_limit="2.67" upper_limit="4.21"/>
                    <measurement group_id="O2" value="4.17" lower_limit="3.32" upper_limit="5.24"/>
                    <measurement group_id="O3" value="4.80" lower_limit="3.81" upper_limit="6.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="207"/>
                    <count group_id="O3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.21" lower_limit="4.25" upper_limit="6.39"/>
                    <measurement group_id="O2" value="1.98" lower_limit="1.61" upper_limit="2.44"/>
                    <measurement group_id="O3" value="0.38" lower_limit="0.32" upper_limit="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="207"/>
                    <count group_id="O3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.55" lower_limit="4.33" upper_limit="7.12"/>
                    <measurement group_id="O2" value="1.82" lower_limit="1.44" upper_limit="2.30"/>
                    <measurement group_id="O3" value="3.41" lower_limit="2.62" upper_limit="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="207"/>
                    <count group_id="O3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.56" lower_limit="9.27" upper_limit="14.40"/>
                    <measurement group_id="O2" value="8.26" lower_limit="6.52" upper_limit="10.47"/>
                    <measurement group_id="O3" value="0.85" lower_limit="0.70" upper_limit="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) of Pneumococcal Serotype-specific Opsonophagocytic Activity (OPA) Antibodies</title>
        <description>OPA for the serotypes contained in V114 was determined using a Multiplex Opsonophagocytic Assay (MOPA-4)</description>
        <time_frame>One month postvaccination</time_frame>
        <population>The analysis population consisted of those participants who were not considered to have violated important protocol requirements that could have impacted the validity of the antibody response measured following vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>V114</title>
            <description>Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>PNEUMOVAX® 23</title>
            <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PNEUMOVAX® 23 on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>PREVNAR 13®</title>
            <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PREVNAR 13® on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) of Pneumococcal Serotype-specific Opsonophagocytic Activity (OPA) Antibodies</title>
          <description>OPA for the serotypes contained in V114 was determined using a Multiplex Opsonophagocytic Assay (MOPA-4)</description>
          <population>The analysis population consisted of those participants who were not considered to have violated important protocol requirements that could have impacted the validity of the antibody response measured following vaccination.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="207"/>
                    <count group_id="O3" value="211"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208.03" lower_limit="156.36" upper_limit="276.78"/>
                    <measurement group_id="O2" value="117.87" lower_limit="87.11" upper_limit="159.49"/>
                    <measurement group_id="O3" value="115.75" lower_limit="85.72" upper_limit="156.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="207"/>
                    <count group_id="O3" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="595.16" lower_limit="498.23" upper_limit="710.95"/>
                    <measurement group_id="O2" value="313.83" lower_limit="256.64" upper_limit="383.76"/>
                    <measurement group_id="O3" value="256.76" lower_limit="212.08" upper_limit="310.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="206"/>
                    <count group_id="O3" value="211"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2875.79" lower_limit="2215.61" upper_limit="3732.69"/>
                    <measurement group_id="O2" value="1099.88" lower_limit="804.01" upper_limit="1504.63"/>
                    <measurement group_id="O3" value="3001.63" lower_limit="2380.57" upper_limit="3784.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="207"/>
                    <count group_id="O3" value="211"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="712.21" lower_limit="537.78" upper_limit="943.22"/>
                    <measurement group_id="O2" value="288.41" lower_limit="210.03" upper_limit="396.06"/>
                    <measurement group_id="O3" value="372.35" lower_limit="271.76" upper_limit="510.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="207"/>
                    <count group_id="O2" value="201"/>
                    <count group_id="O3" value="211"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4216.34" lower_limit="2977.07" upper_limit="5971.49"/>
                    <measurement group_id="O2" value="490.60" lower_limit="325.94" upper_limit="738.44"/>
                    <measurement group_id="O3" value="5251.47" lower_limit="4114.87" upper_limit="6702.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="206"/>
                    <count group_id="O3" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6469.99" lower_limit="4775.27" upper_limit="8766.16"/>
                    <measurement group_id="O2" value="1630.20" lower_limit="1174.34" upper_limit="2263.03"/>
                    <measurement group_id="O3" value="4207.86" lower_limit="3212.46" upper_limit="5511.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 7F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="206"/>
                    <count group_id="O3" value="209"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5148.66" lower_limit="4170.62" upper_limit="6356.06"/>
                    <measurement group_id="O2" value="3665.62" lower_limit="2722.58" upper_limit="4935.30"/>
                    <measurement group_id="O3" value="7816.74" lower_limit="6358.89" upper_limit="9608.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="208"/>
                    <count group_id="O2" value="205"/>
                    <count group_id="O3" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3024.34" lower_limit="2338.72" upper_limit="3910.96"/>
                    <measurement group_id="O2" value="1674.44" lower_limit="1252.72" upper_limit="2238.12"/>
                    <measurement group_id="O3" value="2471.10" lower_limit="1882.58" upper_limit="3243.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="207"/>
                    <count group_id="O3" value="209"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4352.27" lower_limit="3374.62" upper_limit="5613.15"/>
                    <measurement group_id="O2" value="3572.27" lower_limit="2667.12" upper_limit="4784.61"/>
                    <measurement group_id="O3" value="4478.38" lower_limit="3647.04" upper_limit="5499.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="205"/>
                    <count group_id="O3" value="211"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4631.86" lower_limit="3730.53" upper_limit="5750.96"/>
                    <measurement group_id="O2" value="2438.57" lower_limit="1839.33" upper_limit="3233.04"/>
                    <measurement group_id="O3" value="3358.41" lower_limit="2665.75" upper_limit="4231.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19A</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="206"/>
                    <count group_id="O3" value="211"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3391.18" lower_limit="2755.18" upper_limit="4174.00"/>
                    <measurement group_id="O2" value="2682.65" lower_limit="2095.62" upper_limit="3434.12"/>
                    <measurement group_id="O3" value="4186.28" lower_limit="3421.20" upper_limit="5122.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="208"/>
                    <count group_id="O2" value="206"/>
                    <count group_id="O3" value="209"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1201.17" lower_limit="906.20" upper_limit="1592.15"/>
                    <measurement group_id="O2" value="1581.60" lower_limit="1211.55" upper_limit="2064.67"/>
                    <measurement group_id="O3" value="1946.04" lower_limit="1547.41" upper_limit="2447.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 22F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="208"/>
                    <count group_id="O2" value="203"/>
                    <count group_id="O3" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8329.52" lower_limit="6542.87" upper_limit="10604.06"/>
                    <measurement group_id="O2" value="4382.78" lower_limit="3359.60" upper_limit="5717.58"/>
                    <measurement group_id="O3" value="57.45" lower_limit="37.29" upper_limit="88.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="208"/>
                    <count group_id="O2" value="206"/>
                    <count group_id="O3" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2217.18" lower_limit="1588.99" upper_limit="3093.71"/>
                    <measurement group_id="O2" value="378.41" lower_limit="262.42" upper_limit="545.67"/>
                    <measurement group_id="O3" value="1197.80" lower_limit="836.80" upper_limit="1714.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 33F</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="207"/>
                    <count group_id="O3" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31116.90" lower_limit="24612.69" upper_limit="39339.94"/>
                    <measurement group_id="O2" value="27560.15" lower_limit="21471.19" upper_limit="35375.88"/>
                    <measurement group_id="O3" value="3129.94" lower_limit="2441.58" upper_limit="4012.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 months postvaccination</time_frame>
      <desc>The at-risk population consisted of all participants who received study vaccination and had safety follow-up.</desc>
      <group_list>
        <group group_id="E1">
          <title>V114</title>
          <description>Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>PNEUMOVAX® 23</title>
          <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PNEUMOVAX® 23 on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>PREVNAR 13®</title>
          <description>Healthy adult participants received a single 0.5 mL intramuscular injection of PREVNAR 13® on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Benign urinary tract neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="149" subjects_at_risk="230"/>
                <counts group_id="E3" subjects_affected="141" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="68" subjects_affected="57" subjects_at_risk="229"/>
                <counts group_id="E2" events="89" subjects_affected="63" subjects_at_risk="230"/>
                <counts group_id="E3" events="75" subjects_affected="55" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="37" subjects_affected="34" subjects_at_risk="229"/>
                <counts group_id="E2" events="34" subjects_affected="34" subjects_at_risk="230"/>
                <counts group_id="E3" events="31" subjects_affected="30" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="35" subjects_affected="34" subjects_at_risk="229"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="230"/>
                <counts group_id="E3" events="29" subjects_affected="29" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="145" subjects_affected="138" subjects_at_risk="229"/>
                <counts group_id="E2" events="126" subjects_affected="118" subjects_at_risk="230"/>
                <counts group_id="E3" events="137" subjects_affected="122" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="48" subjects_affected="46" subjects_at_risk="229"/>
                <counts group_id="E2" events="26" subjects_affected="25" subjects_at_risk="230"/>
                <counts group_id="E3" events="42" subjects_affected="42" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="45" subjects_affected="41" subjects_at_risk="229"/>
                <counts group_id="E2" events="37" subjects_affected="26" subjects_at_risk="230"/>
                <counts group_id="E3" events="41" subjects_affected="29" subjects_at_risk="230"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="74" subjects_affected="69" subjects_at_risk="229"/>
                <counts group_id="E2" events="72" subjects_affected="60" subjects_at_risk="230"/>
                <counts group_id="E3" events="60" subjects_affected="50" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="43" subjects_affected="40" subjects_at_risk="229"/>
                <counts group_id="E2" events="55" subjects_affected="41" subjects_at_risk="230"/>
                <counts group_id="E3" events="53" subjects_affected="42" subjects_at_risk="230"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

